Healthcasts Media’s Post

With #SABCS23 in full swing, hear from Stefan Faderl, VP, Therapeutic Area Head, Oncology Clinical Development, as he delves into the science behind treating #HER2 positive #breastcancer with targeted therapies: https://lnkd.in/e8eDYyyU   We recognize that a one-size-fits-all approach does not work in the treatment of #cancer, which is why we are pioneering new pathways into novel mechanisms for tumor types like breast cancer.  

Oncology has become a major focus of clinical trials. Did you know that methotrexate, initially for psoriasis, was one of the first chemotherapy drugs discovered? In the 1950s, it was found to slow cancer cell growth. Clinical trials have since ensured it is repurposed for safety and efficacy in treating leukemia, lymphoma, and breast cancer. Learn more about clinical trials: https://lnkd.in/eZUbVKC6

At the 2023 American Society of Clinical Oncology (ASCO) annual meeting, Matthew Ballo, MD, discussed the survival benefit tumor treating fields provide to patients with newly diagnosed #glioblastoma. Learn more here: https://lnkd.in/ekYWZmWz #ASCO23 West Cancer Center & Research Institute

ASCO 2024 research highlights As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. https://lnkd.in/e2DFMtMg #ASCO24 #ASCO #Oncology

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dPW-ansy  #EHA24 #Lymphoma

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d8jmcNPw #EHA24 #Lymphoma

Significant updates from this year's ASCO Annual Meeting could reshape the treatment landscape for various cancers. Watch our panel discussion featuring Oncology Data Advisor Editorial Board members Dr. Matthew Hadfield, Dr. Samuel Kareff, Dr. Morana Vojnic, and Dr. Nagashree Seetharamu as they discuss advances in melanoma, lung cancer, head and neck cancer, brain cancer, CNS metastases, and more. Gain insights into how these developments can improve patient outcomes and hear our experts answer audience questions to put these advancements into context. 🔗 Watch the full panel discussion here: https://bit.ly/3RWHiKi #ASCO2024 #CancerResearch #Oncology #Healthcare #ProfessionalDevelopment

Our Phase I TRANSCEND trial demonstrated that Liso-cel results in consistently high objective response rates - Michael Wang MD Anderson Cancer Center https://lnkd.in/gwa3WF-P #Cancer #CellularTherapy #HighRiskDisease #Lymphoma #OncoDaily #Oncology #StemCellTransplantation

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: https://lnkd.in/e5W5Q496 #Oncology #Immunotherapy #Biomarkers

Its my pleasure to share with you all another great molecular tumor board led by Rebecca Previs and Kyle Strickland. In this knowledge packed tumor board, I discuss very unique tumor micro environment findings. For patients with advanced stage or recurrent uterine cancer, the incorporation of immunotherapy has improved patient outcomes. Hear our discussion of a patient with advanced stage uterine cancer where we discuss the unique immune biomarkers on the OmniSeq INSIGHT® test and implications for therapy. #tumormicroenvironment #cancer #cancerawareness #endometrialcancer #uterinecancer #msi #tmb #immunotherapy #immunooncology #tumor #oncology